Real-world Aliskiren Use in Diabetic Patients
NCT01393860 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2011-07-14
Summary
The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Phamaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-12-31
- Primary Completion
- 2011-06-30
Countries
- United States
Study Locations
More Related Trials
-
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT01165268 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
NCT00938158 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Patients With Diabetic Kidney Disease
NCT06187493 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus
NCT04707508 ·Status: COMPLETED ·Phase: PHASE4
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NCT06651021 ·Status: COMPLETED ·Phase: PHASE1
-
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
NCT00461006 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
NCT05373004 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
NCT06031389 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
NCT01316094 ·Status: COMPLETED ·Phase: PHASE3
-
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
NCT00320879 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
NCT02981966 ·Status: COMPLETED ·Phase: PHASE4
-
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580 ·Status: COMPLETED
-
Renal Impairment Study With ASP1941
NCT01302028 ·Status: COMPLETED ·Phase: PHASE1
-
OPTIMISE-CKD Drug Utilization
NCT05932901 ·Status: COMPLETED
-
Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria
NCT02807974 ·Status: COMPLETED ·Phase: PHASE3
-
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
NCT05998837 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
NCT01069926 ·Status: COMPLETED ·Phase: PHASE1
-
Shiga Microalbuminuria Reduction Trial-2
NCT01461499 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
NCT03036150 ·Status: COMPLETED ·Phase: PHASE3
-
Study Of Diabetic Nephropathy With Atrasentan
NCT01858532 ·Status: TERMINATED ·Phase: PHASE3
-
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
NCT02695082 ·Status: COMPLETED
-
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
NCT03795389 ·Status: COMPLETED ·Phase: PHASE1
-
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05897372 ·Status: TERMINATED ·Phase: PHASE2
-
Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
NCT00192803 ·Status: UNKNOWN ·Phase: PHASE4